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How Many Ways Can a Podocyte Die?
Pierre-Louis Tharaux, MD, PhD,*,†,‡ and Tobias B. Huber, MD§,
Summary: Podocytes are highly specialized epithelial cells that line the urinary surface of the glomerular capillary
tuft. To maintain kidney filtration, podocytes oppose the high intraglomerular hydrostatic pressure, form a
molecular sieve, secrete soluble factors to regulate other glomerular cell types, and provide synthesis and
maintenance of the glomerular basement membrane. Impairment of any of these functions after podocyte injury
results in proteinuria and possibly renal failure. Loss of glomerular podocytes is a key feature for the progression
of renal diseases, and detached podocytes can be retrieved in the urine of patients with progressive glomerular
diseases. Thus, the concept of podocyte loss as a hallmark of progressive glomerular disease has been widely
accepted. However, the nature of events that promote podocyte detachment and whether detachment is preceded
by any kind of podocyte cell death, such as apoptosis, necroptosis, or necrosis, still remains unclear and is
discussed in this review.
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iThe development of glomerular sclerosis in severalhuman and experimental diseases is associatedwith a decrease in the number of podocytes in the
glomerular capillary tuft.1-5 In particular, glomerular in-
jury and proteinuria in diabetes (types 1 and 2)4-8 and IgA
nephropathy3,9 are related to the degree of podocyte de-
pletion in human beings. In agreement with these find-
ings, a number of seminal studies in Japan have described
podocalyxin-positive cells in urinary sediments of pa-
tients suffering from a variety of kidney diseases.9-15 In
addition, changes in semiquantitative measures of podo-
cyturia seem to correlate directly with disease activity as
assessed by biopsy and to decline with treatment,16,17
suggesting that urinary shedding of podocytes may rep-
resent a real-time measure of podocyte loss from the
glomerulus. Experimentally, the causal relationship be-
tween podocyte depletion and glomerulosclerosis was
examined in toxic models of podocyte depletion. Sequen-
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394ial podocyte depletion by 15%, 31%, and 53% was
chieved by the administration of one, two, or three,
espectively, injections of puromycin aminonucleoside
PAN) at 30-day intervals in rats. Regions of the glom-
rulus devoid of podocytes developed glomerulosclero-
is, and the sclerosis progressed with the ongoing deple-
ion of podocytes.1 Similar results were obtained by using
a transgenic rat strain in which the human diphtheria
toxin receptor was expressed specifically in podocytes.18
In this model, glomerulosclerosis also was correlated to
the extent of podocyte diphtheria toxin (DT)-induced
depletion. By using a mouse model with podocyte ex-
pression of the human alpha chain of the IL-2 receptor
(hCD25), which is the receptor for the immunotoxin
LMB2 (a fusion of a single-chain Fv fragment of the
CD25-specific, anti-Tac mAb to a truncated form of the
bacterial Pseudomonas exotoxin A), Matsusaka et al19,20
observed that, again, injection of the anti-Tac (Fv)-PE38
(LMB2) immunotoxin dose-dependently promoted podo-
cyte foot process effacement, vacuolar degeneration, de-
tachment, and down-regulation of synaptopodin, WT-1,
nephrin, and podocalyxin, with subsequent focal segmen-
tal glomerular sclerosis. Furthermore, this group ob-
served spreading of podocyte damage and detachment to
podocytes that had not been targeted initially, suggesting
that podocyte damage may propagate injury by triggering
secondary damage of remnant podocytes.20 During glo-
erular injury, podocytes retract and broaden their foot
rocesses and may detach from the glomerular basement
embrane. As a consequence of significant podocyte
oss, the remaining podocytes are likely to fail to com-
letely cover the outer surface of the glomerular base-
ent membrane (GBM).
However, despite strong evidence that podocyte loss is
prerequisite for glomerulosclerosis, there is very lim-
ted insight into the nature of events that promote podo-
yte detachment. In particular, it is not clear whether
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Podocyte death 395podocytes detach because they die or because of the
primary loss of adhesion.
In other conditions, such as collapsing glomerulopathy
(CGP) and crescentic glomerulonephritis (GN), podocyte
loss occurs after a transient phase of proliferation. This
could induce severe detrimental effects in such termi-
nally differentiated cells, which are not equipped to face
a sustained mitotic process.
We suggest that improved knowledge of the pathways
that mediate podocyte loss should help identify potential
upstream and downstream signals as novel therapeutic
targets to protect against glomerular disease progression.
MECHANISMS OF PODOCYTE CELL DEATH
Three major morphologies of cell death have been de-
scribed: apoptosis (type I), cell death associated with
autophagy (type II), and necrosis (type III), with a re-
cently described subcategory of regulated necrosis
(necroptosis).21-24 Apoptosis and cell death associated
with autophagy can be distinguished by certain biochem-
ical events. Morphologic changes associated with apo-
ptosis are evident in the nucleus with chromatin conden-
sation followed by nuclear fragmentation, zeiosis
(membrane blebbing), and formation of intranuclear and
extranuclear apoptotic bodies. The membrane-bound ap-
optotic bodies contain organelles that appear intact, un-
like during autophagy, and some of these bodies contain
nuclear fragments. As apoptosis evolves in cultured cells,
massive cell swelling is observed, suggesting plasma
membrane fragmentation. Necrosis is characterized
mostly in negative terms by the absence of features
associated with apoptosis, such as caspase activation,
cytochrome c release, and DNA oligonucleosomal frag-
mentation. A particular difficulty in defining necrosis is
that in the absence of phagocytosis, a situation that ap-
plies to podocytes, apoptotic cells can become secondary
necrotic cells that have many morphologic features of
primary necrosis.
APOPTOSIS
In the absence of a molecular marker for apoptosis, electron
microscopy remains the gold standard for the identification
of this elusive form of cell death.25,26 Terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate
nick-end labeling (TUNEL) is a sensitive method, but it can
generate false positives.27,28 A critical point for the quanti-
tation of apoptosis is that, irrespective of the initiating insult,
the time-course of apoptosis is very fast.29,30 Usually, the
clearance of the resultant debris (either by professional
phagocytes or bystander phagocytes) is rapid and completed
within hours. In the putative case of podocyte apoptosis,
phagocytosis is not likely to occur, but detachment may
occur rapidly, resulting in a low probability that apoptotic
cells are observed.
Nevertheless, the first signs of apoptotic cell death are
a condensation of the nuclear material, with a marked saccumulation of densely stained chromatin, typically at
the edge of the nucleus. This is accompanied by cell
shrinkage. Cytoplasmic condensation is accompanied by
break up of the cell into a number of membrane-bound,
ultrastructurally well-preserved fragments. Cytoplasmic
blebs appear on the cell surface,31 and the cell detaches
from its neighbors. In the second stage, these apoptotic
bodies are shed from epithelial-lined surfaces or are
taken up by other cells. Eventually, the cells themselves
fragment, with the formation of a number of membrane-
bound apoptotic bodies. The morphologic features of
apoptosis have been reviewed extensively.21,32-34
Evidence for Apoptosis in Experimental Diabetic
Nephropathy
Evidence for TUNEL-positive podocyte death is scarce.
In one study, positive TUNEL staining indicated that
apoptosis was present in approximately half of the uri-
nary podocytes examined.35 Apoptosis of glomerular
podocytes in situ has been described in animal models of
progressive glomerular sclerosis,36-38 at the onset of hy-
perglycemia in Ins2 (Akita) mice with type 1 diabetes
and Lepr (db/db) mice with obesity and type 2 diabetes,
rats after chronic infusion of angiotensin II (AngII),39 and
in the very specific transforming growth factor-1 (TGF-
1) transgenic mice model. TGF-1 and Smad7 each
induce apoptosis in cultured podocytes, and their co-
expression has an additive effect. Activation of p38
mitogen-activated protein kinase and caspase-3 is re-
quired for TGF-–mediated apoptosis, but not for
Smad7-mediated apoptosis, which inhibits nuclear trans-
location and transcriptional activity of the cell survival
factor nuclear factor-B (NF-B).38 Interestingly, in di-
abetic models, podocyte apoptosis coincided with the
onset of urinary albumin excretion and preceded signif-
icant losses of podocytes in Akita (37% reduction) and
db/db (27% reduction) mice.40 Such events may be tran-
sient or specific to pathophysiological conditions, with
few other reports of in vivo apoptosis of podocytes, such
as in models with forced expression of PDGF-D41 or
eletion of the estrogen receptor.42 In addition, it should
e noted that the detected rates of TUNEL-positive podo-
ytes in vivo have been very small.
xtrinsic Apoptosis Downstream the TNF-alpha Pathway
ome mechanistic insight is provided by the autosomal-
ecessive Alport nephropathy in collagen 4a3–deficient
ice. This model is associated with increased intrarenal
xpression of the pro-apoptotic cytokine tumor necrosis
actor- (TNF-) in glomerular cells, including podo-
cytes as well as infiltrating leukocytes. Podocyte rarifi-
cation develops over time with glomerulosclerosis.
TNF- dose-dependently promotes podocyte apoptosis
n culture.43 A beneficial effect of the TNF- antagonist
tanercept shown on a 5-week survival period was asso-
iated with significant improvement of the glomerulo-
clerosis score, proteinuria, and the glomerular filtration
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396 P.-L. Tharaux and T.B. Huberrate at 9 weeks of age. Etanercept treatment specifically
reduced the numbers of apoptotic podocytes (TUNEL),
increased total podocyte counts, and increased the renal
messenger RNA expression of nephrin and podocin with-
out affecting markers of renal inflammation.44 Thus, this
study suggests that some degree of “extrinsic apoptosis”
may occur in podocytes of collagen 4a3–deficient mice.
The term extrinsic apoptosis has been used extensively to
indicate instances of apoptotic cell death induced by
extracellular stress signals that are sensed and propagated
by specific transmembrane receptors.45,46 Extrinsic apo-
ptosis can be initiated by the binding of lethal ligands,
such as the apoptosis stimulating fragment FAS/CD95
ligand, TNF-, and TNF (ligand) superfamily member
10 (best known as TNF-related apoptosis-inducing li-
gand), to various death receptors (ie, FAS/CD95, TNF-a
receptor 1).24 There is a current consensus that extrinsic
apoptosis is a caspase-dependent cell death subroutine
and hence can be suppressed by pancaspase chemical
inhibitors. Notably, TNF- stimulation of a human podo-
cyte cell line did not lead to any detectable levels of
phosphatidylserine exposure to the extracellular environ-
ment,47 indicating that specific in vivo conditions such as
specific glomerular basement membrane composition
may be required to promote extrinsic apoptosis. Extrinsic
apoptosis would feature one of three major lethal signal-
ing cascades: (1) death receptor signaling and activation
of the caspase-8 (or 10)–caspase-3 cascade; (2) death
receptor signaling and activation of the caspase-8-trun-
cated BH3 interacting-domain death agonist (tBID)- mi-
tochondrial outer membrane permeabilization (MOMP)-
caspase-9– caspase-3 pathway; or (3) ligand deprivation-
induced dependence receptor signaling followed by
(direct or MOMP-dependent) activation of the caspase-
9–caspase-3 cascade.24 Other stimuli such as increased
oxidative stress also were shown to promote apoptosis of
cultured podocytes.40 Eight days after the onset of exper-
imental crescentic rapidly progressive glomerulonephri-
tis,48 or after 28 days of chronic AngII infusion (unpub-
lished data), we failed to find TUNEL-positive cells and
electron microscopy features of apoptosis in mouse
glomeruli, suggesting that apoptosis is scarce or an early
event in these conditions. During aging, the amount of
apoptotic cells assessed by TUNEL staining in 9-month-
old rats was increased compared with 1-month-old rats.
Apoptotic cells were rare overall but increased continu-
ously with age. Interestingly, they almost always were
found in tubules and interstitial cells, rather than in
glomeruli.49
Taken together, experimental data indicate that apo-
ptosis is observed much more often in cultured podocytes
than in podocytes in vivo, where apoptosis has been
reported only under a few conditions and at very low
rates. This might suggest that podocyte apoptosis is not a
general pathway of podocyte loss in vivo, and it remains
unclear whether podocytes are shed because they un-
dergo necrosis or apoptosis in situ, or if they still areiable when they detach from the glomerular basement
embrane.
Loss of Mitotic Arrest,
Abnormal Balance of Cell-Cycle Proteins
As reviewed elsewhere, during development, podocytes
lose their mitotic activity concurrent with the formation
of foot processes and the expression of specific makers.50
At the capillary loop stage, a switch of expression in
cyclins and cyclin-dependent kinase inhibitors is ob-
served with the disappearance of cyclin A, B1, and D1
along with up-regulation of p27 and p57 and specific
podocyte markers.51 Thus, podocytes are locked in the
1 arrest of the cell cycle. In the context of crescentic
lomerulonephritis, epithelial cells forming the crescent
ere shown to be negative for p27 and p57 and positive
or proliferating cell nuclear antigen (PCNA).52 Expres-
ion of cyclin-dependent kinases such as cyclin-depen-
ent kinase (CDK)2 is enhanced in experimental cres-
entic glomerulonephritis in mice, and diminution of
DK2 activity with the purine analogue roscovitine ame-
iorates histopathologic damage.53,54
CGP was recognized early as an entity distinct from
ocal segmental glomerulosclerosis (FSGS).55 Podocyte
njury in CGP is characterized by a dedifferentiated phe-
otype as indicated by the loss of expression of maturity
arkers, re-expression of proliferative markers (Fig.
)52,56,57 and the acquisition of a macrophage-like pheno-
ype.58,59 These features are partially reminiscent of cres-
entic GN with abnormal distribution of WT1 and PAX2
nd extensive loss of podocyte markers, as reported in
diopathic collapsing glomerulopathy and human immu-
odeficiency virus (HIV)-associated nephropathy. This
Figure 1. PCNA (Proliferating Cell Nuclear Antigen) staining in
FSGS. In the upper glomerulus, black nuclear positivity is seen in
numerous podocytes at the periphery of the glomerular tuft (red
arrows), as well as in parietal epithelial cells (black arrows). In the
lower glomerulus, several parietal epithelial cells are marked as well
as a cell of macrophagic appearance adjacent to the tuft, likely of
podocyte origin. Original magnification x350. Image courtesy of Gary
S. Hill and Dominique Nochy.
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Podocyte death 397deregulation was associated with podocyte proliferation
(PCNA) without detectable apoptosis (TUNEL).60 In
contrast, no podocyte changes were detected in minimal
change nephrotic syndrome (MCNS) or membranous
glomerulonephritis (MGN). Interestingly, in children
with minimal change disease and classic FSGS, Srivas-
tava et al61 showed that podocytes are physiologically
unable to overcome the G1/S transition phase, in contrast
to the deregulated proliferative phenotype of idiopathic
CGP in adults. This interpretation was supported by
observation of de novo cyclin A staining in children with
CGP only, by comparison with children with FSGS and
minimal change disease. The staining of both cyclins D
and A was increased and p27 and p21 was decreased in
CGP, suggesting that during CGP, podocytes are able to
overcome the G1/S transition phase.62 A pathophysiolog-
ical role of activation of cyclins has been shown in a
mouse model.63 The upstream promoters of podocyte
proliferation in CGP still are unknown, although a src-
Sta3–mitogen-activated protein kinase–vascular endothe-
lial growth factor–vascular endothelial growth factor re-
ceptor 2/neuropilin-1 was shown to be involved in nef-
transfected podocytes and transgenic mice.64-66 Notably,
in mouse embryonic kidneys, transgenic HIV mice, and
rats with experimental membranous nephropathy (pas-
sive Heymann nephritis), there was an increase in podo-
cyte immunochemical expression of mitotic cell-cycle
proteins Cdc2, cyclin B1, and B2, and phosphorylated
histone 3 in passive Heymann nephritis rats and in HIV
transgenic mice.67 Thus, mitotic cell-cycle proteins also
may increase in podocytes in conditions with mild or lack
of proliferation.
It still is unknown whether these features of HIV-
associated nephropathy are generalizable to other CGP
and to crescentic GN. The role of the epidermal growth
factor receptor (EGFR) pathway, a potent promoter of
crescent formation,48 should be evaluated in this specific
context as well. It is uncertain how this pathway would
lead to podocyte death. For example, heparin binding-
EGF (HB-EGF)/EGFR activation promotes prolifera-
tion48 and anchorage-independent growth in podocytes,
as may stat3 in nef-expressing podocytes.68 Nevertheless,
histopathologic evidence suggests that neither in the case
of crescentic glomerulonephritis, nor in collapsing glo-
merulopathy, do podocytes proliferate indefinitely. De-
cellularization of glomeruli occurs over time, indicating
that some mode of cell death should take place.
MITOTIC CATASTROPHE
Interestingly, restrictions in a cell’s ability to halt the cell
cycle can cause mitotic catastrophe. Indeed, during mi-
tosis, cells segregate duplicated chromosomes with high
fidelity to maintain genome stability. Proper attachment
of sister kinetochores to spindle microtubules is critical
for accurate chromosome segregation and is driven by
complex mechanisms that promote the capture of unat-
tached kinetochores and the resolution of erroneously pttached kinetochores.69,70 Defects in these surveillance
ystems promote failing mitoses that often are associated
ith chromosomal breaks and deficient karyokinesis,
hich lead to gross nuclear alterations (micronucleation
nd multinucleation) that constitute the most prominent
orphologic traits of the mitotic catastrophe. However,
eatures of apoptosis and necrosis also have been ob-
erved in cells dying from mitotic failure, raising the
ossibility that mitotic catastrophe might constitute a
relude to apoptotic or necrotic cell death rather than a
ell death mechanism.71,72 Vakifahmetoglu et al72,73 ob-
erved that activation of p53 by cellular stress caused by
isplatin in cultured ovarian carcinoma cells may lead to
ither cell-cycle arrest or apoptotic cell death. Functional
53 and caspase-2 were required for the apoptotic response.
n the absence of functional p53, cisplatin treatment resulted
n caspase-2–independent mitotic catastrophe, followed by
ecrosis. Nevertheless, scarce but noticeable evidence sug-
ests that a mitotic catastrophe occurs in cultured human
lomerular progenitor cells upon activation of Notch.74 Sim-
ilarly, Kriz et al75 encountered features of “abortive mitosis”
n a rat model of FSGS, which is highly suggestive of
itotic catastrophe in podocytes.
Thus, the final mode of cell death may be determined
y the profile of proteins involved in the regulation of the
ell cycle. For example, complex spatiotemporary regu-
ation of cyclin-dependent kinase 1 (Cdk1) contributes to
he mitotic prophase and metaphase but also could lead to
poptosis or to mitotic catastrophe if prematurely acti-
ated.76 We refer to excellent recent reviews on this
phenomenon.77 Whether such a definition applies to ter-
minally differentiated cells such as podocytes requires
further investigation. Interestingly, the Stuart Shank-
land’s laboratory found that high levels of cyclin I in
podocytes activated Cdk5 in isolated mouse podocytes
and neurons, and they proposed that cyclin I-Cdk5 acti-
vates the mitogenactivated protein kinase (MAPK)/extra-
cellular signal regulated kinase (ERK) kinase pathway
and results in increased Bcl-2 and Bcl-X(L) messenger
RNA and protein levels. This pathway was found to be
defective in mice with increased caspase-3 activation in
cyclin I–deficient podocytes after experimental glomer-
ulonephritis induced by the administration of antiglo-
merular serum.78 In fact, lack of cyclin I renders podo-
ytes more susceptible to apoptosis in vitro and in vivo,
feature not observed in mesangial or in tubular cells.54
In a nonproliferative model of glomerulopathy, the fa/fa
Zucker rat, increased expression of cyclin-dependent ki-
nase inhibitors co-exists with vacuolation of podocytes,
suggesting promotion of cell death.50
We thus suspect that proliferation and quiescence are
he result of different podocyte survival strategies. A
uiescent phenotype with a G1 arrest of the cell cycle is
ompatible with high autophagic flux, whereas prolifer-
tive pathways restrain autophagy and disorganize the
pecific podocyte cytoskeleton. Two fates then can be
redicted and should be investigated in further depth: (1)
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398 P.-L. Tharaux and T.B. Huberforced progression to G1/S would require loss of polarity
protein complexes,79 formation of a mitotic spindle, and
loss of foot processes and detachment; and (2) forced
mitosis in such a terminally differentiated postmitotic
cell type also may lead to abnormal mitosis and genomic
instability. Overall, even in diseases associated with tran-
sient proliferation of podocytes, loss of podocytes may
occur not only though dedifferentiation but also through
mitotic catastrophe and detachment. Molecular pathways
still need to be deciphered in more detail in the podocyte.
MORPHOLOGIC AND ULTRASTRUCTURAL
CHARACTERISTICS OF PODOCYTE INJURY AND LOSS
Because available biochemical and fluorescent data are
not conclusive with respect to the mode of podocyte cell
death in vivo, the description of specific morphologic
features of damaged podocytes is important for under-
standing the sequence of events leading to podocyte
detachment and loss.
Mitochondrial Damage
Podocytes are characterized by a prominent nucleus, a
well-developed Golgi system and endoplasmic reticulum,
and abundant mitochondria. The latter was attributed to
the high energy demand of podocytes to maintain various
cellular functions. Mitochondria play a primary role in
maintaining podocyte energy homeostasis80 and repre-
sent one of several possible sources of cellular reactive
oxygen species (ROS). The apoptotic demise of cells can
be triggered by a plethora of intracellular stress condi-
tions, including DNA damage, oxidative stress, cytosolic
Ca2 overload, mild excitotoxicity (related to glutamate-
receptor overstimulation in the nervous system), accumu-
lation of unfolded proteins in the endoplasmic reticulum,
and many other factors. Although the signaling cascades
that trigger intrinsic apoptosis are highly heterogeneous
as far as the initiating stimuli are concerned, they are all
wired to a mitochondrion-centered control mechanism.81
Frequently, along with the propagation of the pro-apop-
totic signaling cascade, anti-apoptotic mechanisms also
are engaged in an attempt to allow cells to cope with
stress. In this scenario, both proapoptotic and antiapop-
totic signals converge at mitochondrial membranes,
which become permeabilized when the former predomi-
nate over the latter.81 Furthermore, the mitochondrial
copy number has been shown to be decreased in focal
segmental glomerulosclerosis induced by PAN.82 How-
ever, the number of podocyte mitochondria was reported
to be increased during the early stage of diabetic ne-
phropathy. Dysmorphic mitochondria frequently are ob-
served in podocytes, and further studies are required to
evaluate potential significance.
In fact, the impact of mitochondrial dysfunction is
equivocal. Necrotic cell death represents a rapid cellular
response involving the production of mitochondrial ROS,
decreased adenosine triphosphate concentration, and ather cellular insults, whereas autophagic cell death first
tarts as a survival attempt by the clean up of ROS-
amaged mitochondria.83 Major MOMP constitutes a
point-of no-return of intrinsic apoptosis.81
Genetic alteration of the mitochondrial genome
roved to influence podocyte fate rather than other glo-
erular cells. An A to G transition at position 3243 in
itochondrial DNA has been described mainly in asso-
iation with mitochondrial myopathy, encephalopathy,
actic acidosis, and stroke-like episodes or progressive
xternal ophthalmoplegia. However, two recent studies
f patients carrying the A3243G mitochondrial DNA
utation with FSGS reported severely damaged podo-
yte changes containing extraordinary dysmorphic mito-
hondria, which may participate in the development of
SGS.84,85 It should be noted that in these specimens,
bnormal mitochondria were accumulated exclusively in
odocytes, whereas both mesangial cells and capillary
ndothelial cells in glomeruli appeared intact. Because
odocytes are highly differentiated terminal cells that do
ot undergo cell division in the postnatal period, these
ells may be susceptible to the accumulation of mutated
itochondria, similar to neural and muscle cells. Because
f the accumulation of these abnormal mitochondria,
itochondrial protein synthesis and energy supply may
e impaired,85 leading to the induction of podocyte dys-
unction followed by the development of FSGS. How-
ver, mitochondrial dysfunction can lead to collapsing
N and crescentic GN. This is the case in primary
oenzyme Q10 (CoQ10) deficiency owing to mutation in
he coenzyme Q2 homolog (COQ2) gene that encodes
he parahydroxybenzoate-polyprenyl-transferase enzyme
f the CoQ10 synthesis pathway.86 COQ2 nephropathy
hould be suspected when electron microscopy shows an
ncreased number of abnormal mitochondria in podo-
ytes and other glomerular cells. Interestingly, in the
ouse kd/kd model of collapsing glomerulopathy, elec-
ron micrographs showed collapsed capillaries, extensive
oot process effacement, and dysmorphic mitochondria in
odocytes.86 In this model, mitochondrial dysfunction
ccurs as a result of a mutation in the gene encoding for
prenyltransferase-like mitochondrial protein that has
xtensive homologies with the human transprenyltrans-
erase (PDSS2) gene, which is involved in the CoQ10
synthesis pathway.
Autophagy
Autophagy is an evolutionarily conserved lysosomal pro-
cess wherein a cell degrades its own cytoplasmic con-
tents.87,88 The term autophagy was coined by Christian de
uve soon after his discovery of lysosomes.89 Autophagy
is extremely important in housekeeping, particularly in
terminally differentiated cells such as neurons88-90 and
odocytes.91 Notably, podocytes were identified as the
cell type with the highest autophagic activity in the
kidney.91,92 Accumulating evidence indicates that the ex-
ct role of autophagy in cell survival versus death is both
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Podocyte death 399stimulus- and context-dependent.93,94 Indeed, autophagy
is well recognized as a survival mechanism during nutri-
ent limitation: through the bulk degradation of cytoplas-
mic material, autophagy generates both nutrients and
energy in starving cells.87,88 Accordingly, during nutrient
starvation, inhibition of autophagy promotes apoptosis,95
and anti-apoptotic Bcl2 inhibits beclin1-dependent au-
tophagy.94,96 In contrast, excessive autophagy has been
proposed to mediate autophagic or type 2 programmed
cell death. For example, L929 fibrosarcoma cells die in
the absence of caspase activity with involvement of au-
tophagy; autophagy related 7 homolog (ATG7) and be-
clin-1 genes are required for this death process.97 In this
model, caspase inhibition induces the selective au-
tophagic degradation of catalase, a major ROS scaven-
ger, and the resulting ROS accumulation promotes type 2
programmed cell death.97,98 Thus, caspase inhibitors may
arrest apoptosis but also have the unanticipated effect of
promoting autophagic cell death in certain conditions.
Interestingly, accumulation of autophagic vacuoles can
precede apoptotic cell death in several cell types or
necroptosis in acute lymphoblastic leukemia cells.99
However, mutual exclusion between the two processes,
apoptosis and autophagy, as described earlier, is com-
mon. For example, RAGE is a positive regulator of
autophagy and a negative regulator of apoptosis during
oxidative stress in pancreatic cancer cells.100 This de-
serves to be investigated in podocyte diseases.101,102 In-
terestingly, glomerular podocytes display very high lev-
els of basal autophagic activity that appear to be crucial
for intracellular protein quality control. Importantly, a
negative association between PAN-induced nephrosis
and the amount of microtubule-associated protein 1
light chain 3 alpha (LC3) in podocytes was recog-
Figure 2. Transgenic green fluorescent protein (GFP)-LC3 mouse m
gosomes, in podocytes. Right panel: higher magnification view of a
fluorescent molecules are visualized in autophagosomes in podocytnized.91 Levels of LC3-II, a marker of autophago- iomes, (Fig. 2) rapidly decrease in podocytes damaged
y PAN but increase during their recovery from the
amage,91 suggesting an association of autophagy with
healthy and differentiated cell status. Beyond this sem-
inal observation, recent mechanistic evidence has sug-
gested that podocyte autophagy is a protective pathway
in glomerular disease and aging.92 Podocyte-specific de-
letion of the Atg5 gene therefore leads to the accumula-
tion of damaged mitochondria oxidized proteins and pro-
tein aggregates. This loss of cellular protein homeostasis
in autophagy-deficient podocytes results in a dramatic
acceleration of glomerular diseases, identifying au-
tophagy as a key homeostatic mechanism to maintain
podocyte integrity under physiological and stress condi-
tions.92 These recent findings underscore the need to
ecipher the network of local regulators of autophagy in
odocytes.
In podocytes, co-activation of the TGF-1 pathway
through engagement of the Notch ligand Jagged 1 was
reported to induce apoptosis, resulting in cell depletion
and FSGS.102 AngII, a known inducer of TGF- activ-
ity,103 also was found to increase staurosporine-induced
apoptosis in vitro,104 likely via the calcineurin-NFAT
(nuclear factor of activated T-cells) cascade.105 Increase
in the calcium influx in response to AngII, caused by
mutation of the transient receptor potential canonical
(TRPC6) channel, promotes excessive podocyte apopto-
sis acutely106,107 and FSGS over time.108 Interestingly,
some features evoking AngII-dependent podocyte apo-
ptosis have been found in vivo,39 particularly after a first
nitial diphtheria toxin–induced podocyte injury,109 sug-
esting again that AngII may be more of a co-factor than
trigger of apoptosis. Paradoxically, AngII may acutely
romote autophagy in cultured podocytes,103 and in vivo
showing the high number of GFP-positive dots, indicating autopha-
within the white square box in the left panel. Clusters of GFP-LC3
hite arrows). Scale bars: 5 m. Image courtesy of Björn Hartleben.odel
fieldnvestigations thus are required. More in-depth examina-
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400 P.-L. Tharaux and T.B. Hubertion of the potential regulation of autophagy and apopto-
sis by potent inducers of podocyte damage, such as AngII
and endothelin-1 (ET-1), is required. Indeed, podocytes
show functional AngII and ET-1 receptors,110-114 as well
as EGFR,48,115 a potent amplifier of their signaling cas-
cades. Transactivation of the EGFR by the AT1-type
AngII receptor or the ETA-type ET-1 receptor115-117 may
in fact inhibit autophagy through activation of the ras-
type I phosphoinositide 3 (PI3)-kinase–mammalian tar-
get of rapamycin (mTOR) pathway.118-122 These factors
may apply to other tyrosine kinase receptors such as the
insulin receptor, because podocyte-specific deletion of
the insulin receptor was sufficient to promote glomeru-
losclerosis.123 Meanwhile, activation of the EGFR also
has been suggested to stimulate autophagy in nonrenal
cells.124-127 Thus, whether part of the nephroprotective
actions of anti-AngII, anti–ET-1, or anti-EGFR therapeu-
Table 1. Summary of the Currently Suspected Death Modes of P
Main Suspected Death Modes for Podocytes
Anoikis Lack of 1 i
Overexpress
Caspase 3 a
Inhibited by
benzyloxyca
Down-regula
Caspase-dependent intrinsic apoptosis Activation o
repress th
Loss of mito
Unligated in
Inhibited by
Caspase-independent intrinsic apoptosis Accumulatio
the interm
Inhibited by
Extrinsic apoptosis caused by death
receptors
Death-recep
BH3 interac
MOMP
Caspase 3 a
Inhibited by
Extrinsic apoptosis caused by death
receptors
Ras hyperac
Lamp-1–pos
No morphol
Methuausis Ras hyperac
Lamp-1–pos
No morphol
Necroptosis Death-recep
activation
No caspase
Receptor tyr
Inhibited by
Autophagic cell death High LC3-ph
P62/seques
Inhibited by
Mitotic catastrophe Leads to ne
Mitotic arres
Aneuploidy
Caspase 2 a
Tumor protei
Inhibited by ptic strategies is owing to stimulation of podocyte au-ophagy remains an open question.91,92 In part, anti-apo-
totic action of autophagy could be attributed to
nhanced clearance of mitochondria by autophagy,
hereby reducing cytosolic cytochrome c release and
ownstream caspase activation after pro-apoptotic in-
ults.128 Therefore, stimulation of autophagy could be a
promising strategy for the treatment of podocytopathies.
Resistance to Anoikis, Modulating
Podocyte Capacity to Survive in Diseases
Evidence from Lemley’s35 laboratory indicates that
nearly half of the podocytes collected from urine of
normal subjects are viable. Moreover, it is possible to
culture and immortalize some of these cells.129 The dif-
ference in growth behavior between healthy controls and
subjects with active glomerular disease suggests that in
ytes
Main Biochemical Description
in activity
f BIM (Bcl-2 interacting mediator of cell death)
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ll leukemia-2 (Bcl-2) expression or caspase Inhibition by N-
yl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk)
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2 homolog region (BH)3-only proteins, which activate or de-
1–3 proteins, such as Bax and Bak, producing MOMP
drial transmembrane potential
3 (ITGB3) induced apoptosis by recruitment of caspase-8
expression or caspase inhibition (Z-VAD-fmk)
apoptosis-inducing factor (AIF) and endonuclease G proteins in
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53 oractive disease, viable podocytes detach from the glomer-
t
b
b
i
f
t
r
p
b
t
d
c
t
Podocyte death 401ular tuft because of local environmental factors, whereas
in healthy individuals it is mostly senescent podocytes
that are shed. Thus, detached podocytes may be resistant
to anoikis. Anoikis, which literally means “the state of
being homeless,” is a term of ancient Greek derivation
that was introduced by Frisch and Francis130 in 1994 to
describe the apoptotic response of adherent cells owing
to the absence of cell-to-matrix interactions.131 The sur-
vival of nontransformed adherent cells does indeed de-
pend on signals transduced by integrins and by some
growth factor receptors upon interaction with the extra-
cellular matrix. In some cancer cells, the resistance to
anoikis of epithelial cancer cells sustains invasiveness
and metastasis. Thus, we hypothesize that during rapidly
progressive glomerulonephritis and collapsing GN, tran-
sient podocyte proliferation with loss of anatomic pat-
terns may be owing to loss of anoikis with abnormal
attachment to the GBM, an effect in part mediated by
activation of the EGFR.48,132 In addition, although stim-
ulation of the TNF receptor may lead to apoptosis (see
earlier), de novo expression of the TNF receptor 2 and
the activated NF-B pathway was detected in podocytes
before hyperplasic injury in crescentic glomerulonephri-
tis of mice after nephrotoxic nephritis and in collapsing
glomerulopathy of Tg26 (HIV/nl) mice, kd/kd mice, and
human beings.133 In this context, some anti-apoptotic
pathways may synergize with the activated NF-B path-
way to promote survival and proliferation.
SUMMARY ANDOUTLOOK
In summary, although apoptosis and necroptosis both
have been observed in podocyte cell lines and primary
cultures, our understanding of the modes of active podo-
cyte death in situ/in vivo are based on a handful of
studies. A salient finding of the recent decade is that
podocytes, some of which still are viable, detach from the
GBM under both physiological and pathologic condi-
tions. In the context of nonproliferative scarring glomeru-
lopathies such as FSGS, it is not clear whether detach-
ment occurs primarily and independently of a cell death
pathway. Evidence for primary or secondary (anoikis)
apoptosis is scarce, possibly because apoptosis unavoid-
ably would lead to rapid podocyte detachment. Another
important finding is the recognition of high autophagic
activity in podocytes. In chronic conditions such as aging
and toxic challenge to podocytes, disruption of au-
tophagy accelerated glomerular damage with extensive
vacuolar degeneration of podocyte cell bodies and foot
process fusion. It will be important to address whether
susceptibility to glomerular aging or scarring disease is
influenced by genetic or environmental determinants of
autophagy.
At the other extremity of the spectrum of podocytopa-
thies, in collapsing glomerulopathy and in inflammatory
extracapillary glomerulonephritis complicating vasculi-
tis, loss of polarization of podocytes and extensions of
parietal cells leads to the loss of the separation betweenhe tuft and Bowman’s capsule by forming cell bridges
etween the glomerular and the parietal basement mem-
ranes. In this context, it is unclear whether autophagy is
nvolved. Some degree of proliferation is observed in the
ormation of epithelial crescents, along with a switch in
he podocyte phenotype. This switch, associated with
e-expression of a fetal gene program, may be incom-
lete, with progression through the G1/S transition phase
ut an inability to sustain normal mitosis. Understanding
he sequence of events leading to podocyte injury and
efining the exact point of no return, beyond which
ytoprotection can no longer be achieved, will be impor-
ant for future podocyte research. (Table 1).
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